AbbVie Showcases Breadth and Depth of Research in Crohn’s Disease and Ulcerative Colitis at UEG Week 2023

– Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA® (ustekinumab) in moderate to severe Crohn’s disease will be presented – Analyses on clinical and endoscopic outcomes from AbbVie’s maintenance trials for SKYRIZI® (risankizumab) and RINVOQ®…